Patents by Inventor Nir LONDON

Nir LONDON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250127783
    Abstract: Disclosed are methods of treating diseases or disorders mediated by dysregulated CDK4/6 and/or Pin 1 activity comprising co-administering a therapeutically effective amount of one or more CDK4/6 inhibitors, and a therapeutically effective amount of one or more Pin1 inhibitors, or a pharmaceutically acceptable salt or salts thereof
    Type: Application
    Filed: September 23, 2022
    Publication date: April 24, 2025
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., BETH ISRAEL DEACONESS MEDICAL CENTER, INC., YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Shizhong KE, Gerburg WULF, Xiao Zhen ZHOU, Nir LONDON, Wenyi WEI, Kun Ping LU, Nathanael S. GRAY, Behnam NABET
  • Publication number: 20240197678
    Abstract: Disclosed are compounds which inhibit Pin1 activity, methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat diseases or disorders characterized or mediated by dysregulated Pin1 activity.
    Type: Application
    Filed: March 18, 2022
    Publication date: June 20, 2024
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., YEDA RESEARCH AND DEVLOPMENT CO. LTD.
    Inventors: Inchul You, Nathanael S. Gray, Tinghu Zhang, Sirano Dhe-Paganon, Nir London, Christian Dubiella
  • Publication number: 20240139326
    Abstract: This invention is directed to substituted a methacrylamide compounds as targeted covalent protein binders and uses thereof.
    Type: Application
    Filed: December 23, 2021
    Publication date: May 2, 2024
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Nir LONDON, Efrat RESNICK, Rambabu REDDI, Adi ROGEL
  • Publication number: 20230406837
    Abstract: Provided herein are Sulfamate compounds for use in modulating an activity of peptidyl-prolyl isomerase NIMA-interacting-1 (Pin1).
    Type: Application
    Filed: June 14, 2023
    Publication date: December 21, 2023
    Applicant: Yeda Research and Development Co., Ltd.
    Inventors: Nir LONDON, Rambabu Reddi
  • Publication number: 20210332024
    Abstract: Disclosed herein are compounds comprising an electrophilic moiety and rigid moiety for use in modulating an activity of Pin1. The rigid moiety comprises at least one functional group that is capable of forming hydrogen bonds with hydrogen atoms, wherein the electrophilic moiety and the rigid moiety are arranged such that the electrophilic moiety is capable of covalently binding to the Cys113 residue of Pin1, and the rigid moiety is capable of forming hydrogen bonds with the Gln131 and His 157 residues of Pin1. Further disclosed are novel compounds having Formula Id: wherein the dashed line, W, X, Y, Z, Ra-Rc, R1, R2, L1, L2 and n are as defined herein, and libraries comprising such compounds. Further disclosed are methods of identifying a compound capable of modulating an activity of Pin1, by screening a library of compounds.
    Type: Application
    Filed: July 8, 2021
    Publication date: October 28, 2021
    Applicants: Yeda Research and Development Co. Ltd., Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Nir LONDON, Daniel ZAIDMAN, Christian DUBIELLA, Nathanael S. GRAY, Benika Joan PINCH, Kun Ping LU, Alfred Thomas LOOK, Shuning HE, Xiao Zhen ZHOU, Xiaolan LIAN
  • Publication number: 20210238173
    Abstract: Provided are compounds that act as covalent inhibitors of mitogen-activated protein kinase kinase 7 (MKK7 enzyme), method of preparation and uses thereof.
    Type: Application
    Filed: June 4, 2019
    Publication date: August 5, 2021
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Nir LONDON, Amit SHRAGA, Evgenia OLSHVANG
  • Publication number: 20190327974
    Abstract: This invention is directed to synergists for organophosphate (OP), carbamate (CM) and/or pyrethroid/synthetic pesticides (SP). This invention is further directed to a composition comprising organophosphate, carbamate, and/or pyrethroid/synthetic pyrethroid, and at least one boronic acid derivative. This invention further provides methods for killing insect pests.
    Type: Application
    Filed: January 9, 2018
    Publication date: October 31, 2019
    Applicants: THE AUSTRALIAN NATIONAL UNIVERSITY, YEDA RESEARCH AND DEVELOPMENT CO. LTD., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Colin JACKSON, Nir LONDON, Galen CORREY, Janelle SAN JUAN
  • Patent number: 10118934
    Abstract: Compounds and salts thereof which inhibit microbial growth or attenuate the virulence of pathogenic microorganisms and which inhibit UDP-galactopyranose mutase (UGM). Compounds of the invention include triazolothiadiazines, particularly 3, 6, 7-substituted-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines, and 4-(1H-pyrrol-3-yl) thiazoles, particularly 4-(1,2,5-substituted-1H-pyrrol-3-yl)-2-substituted thiazoles, and salts thereof. Methods for inhibiting growth or attenuating virulence of microbial pathogens including mycobacterium, for example, M. tuberculosis and M. smegmatis and Klebsiella, for example, Klebsiella pneumoniae. Methods for inhibiting eukaryotic human and animal pathogens, and fungi and nematodes in particular. Methods for treatment of infections by prokaryotic and eukaryotic pathogens employing compounds of the invention.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: November 6, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Laura L. Kiessling, Virginia A. Kincaid, Nir London, Brian K. Shoichet
  • Publication number: 20170283437
    Abstract: Compounds and salts thereof which inhibit microbial growth or attenuate the virulence of pathogenic microorganisms and which inhibit UDP-galactopyranose mutase (UGM). Compounds of the invention include triazolothiadiazines, particularly 3, 6, 7-substituted-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines, and 4-(1H-pyrrol-3-yl) thiazoles, particularly 4-(1,2,5-substituted-1H-pyrrol-3-yl)-2-substituted thiazoles, and salts thereof. Methods for inhibiting growth or attenuating virulence of microbial pathogens including mycobacterium, for example, M. tuberculosis and M. smegmatis and Klebsiella, for example, Klebsiella pneumoniae. Methods for inhibiting eukaryotic human and animal pathogens, and fungi and nematodes in particular. Methods for treatment of infections by prokaryotic and eukaryotic pathogens employing compounds of the invention.
    Type: Application
    Filed: June 14, 2017
    Publication date: October 5, 2017
    Inventors: Laura L. KIESSLING, Virginia A. KINCAID, Nir LONDON, Brian K. SHOICHET
  • Patent number: 9708344
    Abstract: Compounds and salts thereof which inhibit microbial growth or attenuate the virulence of pathogenic microorganisms and which inhibit UDP-galactopyranose mutase (UGM). Compounds of the invention include triazolothiadiazines, particularly 3,6,7-substituted-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines, and 4-(1H-pyrrol-3-yl) thiazoles, particularly 4-(1,2,5-substituted-1H-pyrrol-3-yl)-2-substituted thiazoles, and salts thereof. Methods for inhibiting growth or attenuating virulence of microbial pathogens including mycobacterium, for example, M. tuberculosis and M. smegmatis and Klebsiella, for example, Klebsiella pneumoniae. Methods for inhibiting eukaryotic human and animal pathogens, and fungi and nematodes in particular. Methods for treatment of infections by prokaryotic and eukaryotic pathogens employing compounds of the invention.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: July 18, 2017
    Assignees: Wisconsin Alumni Research Foundation, The Regents of the University of California
    Inventors: Laura L. Kiessling, Virginia A. Kincaid, Nir London, Brian K. Shoichet
  • Publication number: 20150344501
    Abstract: Compounds and salts thereof which inhibit microbial growth or attenuate the virulence of pathogenic microorganisms and which inhibit UDP-galactopyranose mutase (UGM). Compounds of the invention include triazolothiadiazines, particularly 3,6,7 -substituted-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines, and 4-(1H-pyrrol-3-yl) thiazoles, particularly 4-(1,2,5-substituted-1H-pyrrol-3-yl)-2-substituted thiazoles, and salts thereof. Methods for inhibiting growth or attenuating virulence of microbial pathogens including mycobacterium, for example, M. tuberculosis and M. smegmatis and Klebsiella, for example, Klebsiella pneumoniae. Methods for inhibiting eukaryotic human and animal pathogens, and fungi and nematodes in particular. Methods for treatment of infections by prokaryotic and eukaryotic pathogens employing compounds of the invention.
    Type: Application
    Filed: June 2, 2015
    Publication date: December 3, 2015
    Inventors: Laura L. KIESSLING, Virginia A. KINCAID, Nir LONDON, Brian K. SHOICHET